

# Clinical trials of Tirofiban

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 acute myocardial infarction

| Trial  | Treatments   | Patients              | Trials design and methods |
|--|--|-----------------------|---------------------------|
| <b>Tirofiban vs primary intervention</b>                                 |  |                       |                           |
| <b>On-Time (vant Hof) , 2004</b><br>n=245/247<br>follow-up: 65279;30-day | facilitated PCI with Tirofiban; 10 g/kg intravenous bolus, 015 g/kg per min infusion versus primary intervention | symptom duration <6h  |                           |
| <b>TIGER-PA (Lee) , 2003</b><br>n=50/50<br>follow-up: 30-day             | facilitated PCI with Tirofiban; 10 g/kg intravenous bolus, 015 g/kg per min infusion versus primary intervention | symptom duration <12h |                           |
| <b>Cutlip , 2003</b><br>n=28/30<br>follow-up: 30-day                     | facilitated PCI with Tirofiban; 10 g/kg intravenous bolus, 015 g/kg per min infusion versus primary intervention | symptom duration <12h |                           |

More details and results :

- myocardial revascularization for acute myocardial infarction in facilitated PCI at <http://www.trialresultscenter.org/go-Q90>

## References

### **On-Time (vant Hof), 2004:**

van 't Hof AW, Ernst N, de Boer MJ, de Winter R, Boersma E, Bunt T, Petronio S, Marcel Gosselink AT, Jap W, Hollak F, Hoorntje JC, Suryapranata H, Dambrink JH, Zijlstra F Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial. Eur Heart J 2004;25:837-46 [15140531]

### **TIGER-PA (Lee), 2003:**

Lee DP, Herity NA, Hiatt BL, Fearon WF, Rezaee M, Carter AJ, Huston M, Schreiber D, DiBattiste PM, Yeung AC Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the Tirofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) pilot trial. Circulation 2003;107:1497-501 [12654606]

### **Cutlip, 2003:**

Cutlip DE, Ricciardi MJ, Ling FS, Carrozza JP Jr, Dua V, Garringer J, Giri S, Caputo RP Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction. Am J Cardiol 2003;92:977-80 [14556878]

## 2 percutaneous coronary intervention

| Trial                       | Treatments | Patients                  | Trials design and methods |
|-----------------------------|------------|---------------------------|---------------------------|
| <b>Tirofiban vs placebo</b> |            |                           |                           |
| RESTORE , 1997<br>n=NA      | -          | PCI <72 h after USA or MI |                           |
| Kereiakis , 1996<br>n=NA    | -          | -                         |                           |

More details and results :

- antithrombotics for percutaneous coronary intervention in all type of patients at <http://www.trialresultscenter.org/go-Q63>

### References

#### RESTORE, 1997:

Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation 1997;96:1445-53 [9315530]

Gibson CM, Goel M, Cohen DJ, Piana RN, Deckelbaum LI, Harris KE, King SB 3rd Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. J Am Coll Cardiol 1998;32:28-34 [9669245]

#### Kereiakis, 1996:

Kereiakes DJ, Kleiman NS, Ambrose J, Cohen M, Rodriguez S, Palabrica T, Herrmann HC, Sutton JM, Weaver WD, McKee DB, Fitzpatrick V, Sax FL Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol 1996;27:536-42 [8606262]

Entry terms: tirofiban, tirofiban, tirofiban hydrochloride monohydrate, MK 383, MK-383, tirofiban hydrochloride, Aggrastat, Cahill May Roberts brand of tirofiban hydrochloride monohydrate, MSD brand of tirofiban hydrochloride monohydrate, Merck Frosst brand of tirofiban hydrochloride monohydrate, Merck Sharp and Dohme brand of tirofiban hydrochloride monohydrate, Agrastat, Merck brand of tirofiban hydrochloride monohydrate, L 700462, L-700462,